DK0634934T3 - Anvendelse af diætmæssige valleproteiner til behandling af HIV-seropositive individer - Google Patents

Anvendelse af diætmæssige valleproteiner til behandling af HIV-seropositive individer

Info

Publication number
DK0634934T3
DK0634934T3 DK93907682T DK93907682T DK0634934T3 DK 0634934 T3 DK0634934 T3 DK 0634934T3 DK 93907682 T DK93907682 T DK 93907682T DK 93907682 T DK93907682 T DK 93907682T DK 0634934 T3 DK0634934 T3 DK 0634934T3
Authority
DK
Denmark
Prior art keywords
seropositive individuals
whey proteins
treat hiv
hiv seropositive
dietary whey
Prior art date
Application number
DK93907682T
Other languages
English (en)
Inventor
Phil Gold
Gustavo Bounous
Original Assignee
Immunotec Res Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotec Res Corp Ltd filed Critical Immunotec Res Corp Ltd
Application granted granted Critical
Publication of DK0634934T3 publication Critical patent/DK0634934T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK93907682T 1992-04-10 1993-03-22 Anvendelse af diætmæssige valleproteiner til behandling af HIV-seropositive individer DK0634934T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/866,756 US5456924A (en) 1988-12-23 1992-04-10 Method of treatment of HIV-seropositive individuals with dietary whey proteins
PCT/CA1993/000107 WO1993020831A1 (en) 1992-04-10 1993-03-22 Method of treatment of hiv-seropositive individuals with dietary whey proteins

Publications (1)

Publication Number Publication Date
DK0634934T3 true DK0634934T3 (da) 2000-06-13

Family

ID=25348339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93907682T DK0634934T3 (da) 1992-04-10 1993-03-22 Anvendelse af diætmæssige valleproteiner til behandling af HIV-seropositive individer

Country Status (19)

Country Link
US (1) US5456924A (da)
EP (1) EP0634934B1 (da)
JP (1) JP2738592B2 (da)
KR (1) KR100297959B1 (da)
CN (1) CN1070371C (da)
AT (1) ATE187335T1 (da)
AU (1) AU687731B2 (da)
CA (1) CA2090186C (da)
CZ (1) CZ283386B6 (da)
DE (1) DE69327236T2 (da)
DK (1) DK0634934T3 (da)
ES (1) ES2143503T3 (da)
IL (1) IL105339A (da)
MX (1) MX9302057A (da)
NO (1) NO317795B1 (da)
NZ (1) NZ251271A (da)
TW (1) TW384223B (da)
WO (1) WO1993020831A1 (da)
ZA (1) ZA932526B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
CA2165937A1 (en) * 1995-05-09 1996-11-10 Immunotec Research Corporation Ltd. Process for producing an undenatured whey protein concentrate
CA2247860C (en) * 1996-03-06 2002-03-19 I. Belloch Corporation Method for treating liquid materials
WO1997034619A1 (en) * 1996-03-20 1997-09-25 New York Blood Center Methods of treating herpes or chlamydia
US5952009A (en) * 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
EP1094824B1 (en) * 1998-06-10 2006-04-05 Albert B. Crum Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system
US6667063B2 (en) 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
US6203805B1 (en) 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins
US6864242B2 (en) 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20060057131A1 (en) * 2001-12-20 2006-03-16 Eric Simard Malleable protein matrix and uses thereof
FR2840318B1 (fr) * 2002-05-29 2004-12-03 Quoc Kiet Pham Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih
FR2889067B1 (fr) * 2005-07-29 2011-11-11 Cie Laitiere Europeenne "utilisation d'une fraction proteique laitiere pour preparer une composition amincissante et/ou ameliorant la composition corporelle"
DE102006052504A1 (de) 2006-11-06 2008-05-08 Temper, Rupert Verfahren zum Herstellen eines Mittels gegen eine Infektionskrankheit
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
AP2009004963A0 (en) * 2007-02-06 2009-10-31 Cymcorp Internat Inc Novel non-toxic composition and method of using such for treating a degenerative or an immune systemrelated disease
US20100069288A1 (en) * 2008-09-12 2010-03-18 Wulf Droge Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
JP2013079216A (ja) * 2011-10-04 2013-05-02 Snow Brand Milk Products Co Ltd 感覚改善剤
JP6234777B2 (ja) * 2013-10-31 2017-11-22 株式会社日立製作所 光多値送信器および光トランスポンダ
DE102014001037A1 (de) * 2014-01-25 2015-07-30 Gea Tds Gmbh Verfahren und Vorrichtung zur Reduzierung des Wachstums thermophiler Keime in Magermilch
US20190262401A1 (en) 2016-09-23 2019-08-29 Immunotec Inc. Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders
CA2970699A1 (en) 2017-06-14 2018-12-14 Elizabeth E. Ignowski Compositions for increasing resilience to traumatic brain injury
US11944649B2 (en) 2017-07-31 2024-04-02 Immunotec Inc. Compositions and methods for treatment of autism spectrum disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA858533A (en) * 1970-12-15 Lahav Eitan Polypeptidic antibiotic substances derived from casein by fermentation
FR2565985B1 (fr) * 1984-06-19 1987-09-25 Rhone Poulenc Sante Nouvelles substances biologiquement actives obtenues a partir de la caseine bovine, leur procede de preparation et les compositions qui les contiennent
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
EP0338229B1 (de) * 1988-04-19 1993-06-16 Biotest Pharma Gmbh Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
FI892006A (fi) * 1988-04-29 1989-10-30 Phil Gold Lactalbumin saosom tillaeggsaemne i mat.
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
CA2007258A1 (en) * 1989-01-11 1990-07-11 Richard L. Jackson Heparin fraction with anti-hiv activity
EP0385909B1 (en) * 1989-03-03 1994-07-13 MicroGeneSys, Inc. A kit or composition for the prevention or treatment of HIV-1 infections
AU645016B2 (en) * 1989-06-02 1994-01-06 Johns Hopkins University School Of Medicine, The Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
CA2022394A1 (en) * 1989-08-07 1991-02-08 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
DK0790308T3 (da) * 1989-12-22 2007-10-08 Hoffmann La Roche Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
US5112373A (en) * 1991-06-17 1992-05-12 Hung Pham Apparatus for controlling and eliminating vapor emissions at a manicure work station

Also Published As

Publication number Publication date
ES2143503T3 (es) 2000-05-16
NO943804D0 (no) 1994-10-07
CZ246194A3 (en) 1995-04-12
AU687731B2 (en) 1998-03-05
WO1993020831A1 (en) 1993-10-28
US5456924A (en) 1995-10-10
NZ251271A (en) 1998-05-27
CN1070371C (zh) 2001-09-05
CA2090186C (en) 1999-03-16
JP2738592B2 (ja) 1998-04-08
EP0634934B1 (en) 1999-12-08
EP0634934A1 (en) 1995-01-25
JPH07504677A (ja) 1995-05-25
IL105339A (en) 1998-07-15
CN1083704A (zh) 1994-03-16
ATE187335T1 (de) 1999-12-15
NO317795B1 (no) 2004-12-13
DE69327236T2 (de) 2000-03-30
CZ283386B6 (cs) 1998-04-15
CA2090186A1 (en) 1993-10-11
KR950700752A (ko) 1995-02-20
MX9302057A (es) 1994-07-29
NO943804L (no) 1994-10-07
ZA932526B (en) 1994-03-09
IL105339A0 (en) 1993-08-18
KR100297959B1 (ko) 2001-10-24
AU3881293A (en) 1993-11-18
TW384223B (en) 2000-03-11
DE69327236D1 (de) 2000-01-13

Similar Documents

Publication Publication Date Title
DK0634934T3 (da) Anvendelse af diætmæssige valleproteiner til behandling af HIV-seropositive individer
DK148889D0 (da) Fremgangsmaade til foroegelse af extracellulaert adenosin og til stabilisering af mastceller
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
MY102472A (en) Preparation of funtional human urokinase proteins.
DK177286D0 (da) Viruskappeprotein
NO983372L (no) Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter
DE69821740D1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
Miller et al. Plasmodium falciparum: thiol status and growth in normal and glucose-6-phosphate dehydrogenase deficient human erythrocytes
Yamashita et al. Response of superoxide anion production by guinea pig eosinophils to various soluble stimuli: comparison to neutrophils
Fernandez-Sousa et al. Variation of superoxide dismutases during the development of the fruit fly Ceratitis capitata L
DK0502313T3 (da) Fremgangsmåde til sikring af tilstrækkeligt intracellulært glutathion i væv
ATE315393T1 (de) Verwendung von histamin um die blutkonzentration des histamins zu erhöhen
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
NZ235297A (en) Aqueous solution containing a protein and anionic polymer or salt and method of increasing the protein concentration of an aqueous solution
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
Wee et al. Changes in blood cellular components, serum chemical values and serum enzyme activities in Korean native cattle infested with Fasciola hepatica
IOKU Methemoglobin formation from hemoglobin by nitrite ion in the erythrocytes of normal and acatalasemic mice; in vivo and in vitro study
NZ243860A (en) Increasing glutathione levels in human and animal organs using whey protein concentrate
Peters et al. Amino Acids and L-Asparaginase Activity in the Plasma of Owl Monkeys (Aotus trivirgatus)
汪坤熔 et al. Remission of Acute Myelofibrosis after Vitamin D_3 Treatment: A Case Report
築山恭子 et al. Bovine platelet-derived factor showing mitogenic activity on bovine leukemia virus-infected lymphocytes.
MOROZ et al. The relationship of potassium and sodium content, ATPase activity, and ATP content in the blood of burn victims
FR2622108B1 (fr) Preparation de concentres de proconvertine (facteur vii), de facteur antihemophilique b (facteur ix) et d'autres proteines plasmatiques, et leur utilisation therapeutique